AllSci News
Youcare takes Factor XI siRNA into US anticoagulation race
China-based Youcare Pharmaceutical Group (SSE: 688658) received US FDA clearance to proceed with clinical trials of YKYY033 injection, a GalNAc-conjugated...
MSD's China Innovation Center taps InventisBio for small-molecule oncology
Merck & Co. (NYSE: MRK), operating as MSD outside the US and Canada, and China-based InventisBio Co., Ltd. (SSE STAR: 688382) signed a collaboration...
NCI backs Minnesota's off-the-shelf cancer-killing Treg platform
University of Minnesota has received a USD 2.08 million National Cancer Institute P01 renewal to advance off-the-shelf allogeneic immune effector cell...
Patient groups raise alarm over Vykat XR use after seven deaths reported
Three Prader-Willi syndrome (PWS) patient organizations have issued a joint safety statement on diazoxide choline (Vykat XR), the first and only...
Regeneron quietly takes SF3B1-mutant therapy into first-in-human trial
Regeneron Pharmaceuticals (Nasdaq: REGN) has registered a first-in-human clinical trial of REGN17235, an investigational agent targeting clonal...
AC Immune takes Parkinson's vaccine into US trials as Phase II data near
Switzerland-based AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced receipt of US FDA...
PTC, Lilly scoop up Sangamo gene therapies in bankruptcy auction
Richmond, California-based Sangamo Therapeutics (OTC: SGMOQ) has concluded a court-supervised Section 363 asset auction, selecting Eli Lilly and Warren, New...
Boulevard Bio launches with Deerfield backing for IgAN pipeline
New York-based Boulevard Bio has emerged from stealth with USD 65 million in launch financing from Deerfield Management and affiliates, backed by early...
Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decision
Copenhagen-based Zealand Pharma (Nasdaq: ZEAL) has agreed to sell its economic interests in rusfertide (PTG-300) to Royalty Pharma (Nasdaq: RPRX) for USD...
Zipalertinib Phase III win sets up first-line Rybrevant challenge
Taiho Oncology, Japan-based Taiho Pharmaceutical Co., Ltd., and Cambridge, Massachusetts-based Cullinan Therapeutics (Nasdaq: CGEM) announced that...
Simcere's pan-RAS inhibitor SIM0532 entering Phase I study
China-based Simcere Zaiming Pharmaceutical Co., Ltd., the oncology subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096), has initiated a...
Merck KGaA partner Remepy raises USD 36m Series A for 'hybrid drug' platform
Israel-based Remepy, a biotechnology company developing Hybrid Drugs — a class that combines conventional prescription pharmaceuticals with personalized,...
UC Irvine alopecia spinout Amplifica gets Lilly backing in USD 26m Series B
San Diego-based Amplifica Holdings Group, Inc., a clinical-stage biopharmaceutical company developing injectable therapies for androgenetic alopecia (AGA),...
Ivonescimab expands China label as Summit awaits US test
China's National Medical Products Administration (NMPA) has approved a supplemental New Drug Application for ivonescimab (Aqissimab) in combination with...
InduPro raises USD 77m as proximity-guided bispecific ADC enters clinic
Seattle-based InduPro, Inc. has closed a USD 77 million Series B financing and dosed the first patient in a Phase I study of IDP-001, a bispecific...
The AllSci Brief
Free, systematic R&D and deal news. Daily.